Bevenopran

Bevenopran
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 5-[2-Methoxy-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyrazine-2-carboxamide;
CAS Number	676500-67-7;
PubChem CID	10452732;
ChemSpider	8628148;
UNII	IC58Q2EHPJ;
KEGG	D10349;
CompTox Dashboard (EPA)	DTXSID90217963 ;
Chemical and physical data
Formula	C20H26N4O4
Molar mass	386.452 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=C(C=CC(=C1)CNCCC2CCOCC2)OC3=NC=C(N=C3)C(=O)N;
	InChI InChI=1S/C20H26N4O4/c1-26-18-10-15(11-22-7-4-14-5-8-27-9-6-14)2-3-17(18)28-19-13-23-16(12-24-19)20(21)25/h2-3,10,12-14,22H,4-9,11H2,1H3,(H2,21,25); Key:ZGCYVRNZWGUXNQ-UHFFFAOYSA-N;

Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally acting μ-opioid receptor antagonist that also acts on δ-opioid receptors and was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation. It reached phase III clinical trials for this indication before being discontinued.

Legal status

Legal status	Investigational
Identifiers
IUPAC name 5-[2-Methoxy-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyrazine-2-carboxamide
CAS Number	676500-67-7
PubChem CID	10452732
ChemSpider	8628148
UNII	IC58Q2EHPJ
KEGG	D10349
CompTox Dashboard (EPA)	DTXSID90217963
Chemical and physical data
Formula	C₂₀H₂₆N₄O₄
Molar mass	386.452 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES COC1=C(C=CC(=C1)CNCCC2CCOCC2)OC3=NC=C(N=C3)C(=O)N
InChI InChI=1S/C20H26N4O4/c1-26-18-10-15(11-22-7-4-14-5-8-27-9-6-14)2-3-17(18)28-19-13-23-16(12-24-19)20(21)25/h2-3,10,12-14,22H,4-9,11H2,1H3,(H2,21,25) Key:ZGCYVRNZWGUXNQ-UHFFFAOYSA-N